Keyphrases
Antigen-specific
9%
Antigen-specific T Cell Response
9%
Axillary Lymph Node
9%
Axillary Ultrasound
11%
Breast
7%
Breast Cancer
59%
Breast Cancer Patients
24%
Breast Reconstruction
13%
Cancer Immunotherapy
10%
Cancer Neoantigens
11%
Cancer Peptide Vaccine
6%
CD8+
8%
CD8+ T Cell Response
9%
CD8+ T Cells
14%
CDC1
6%
Dendritic Cell Subsets
7%
Dendritic Cells
17%
DNA Vaccine
11%
Ductal Carcinoma in Situ
10%
Early Breast Cancer
18%
Epithelial Cell Adhesion Molecule (EpCAM)
23%
HDR Brachytherapy
7%
Human Breast Cancer
15%
Lymph Node
6%
Mammaglobin
21%
Mastectomy
7%
Metastasis
7%
Metastatic Breast Cancer
13%
Micrometastatic
8%
Molecular Detection
11%
Multi-institutional
6%
Multimarker
8%
Neoadjuvant
7%
Neoadjuvant Chemotherapy
9%
Neoantigen
21%
Neoantigen Vaccine
8%
Pancreatic Adenocarcinoma
8%
Pancreatic Cancer
16%
Pancreatic Ductal Adenocarcinoma
9%
Pathological Complete Response
9%
Peripheral Blood
8%
Programmed Death-ligand 1 (PD-L1)
6%
Quantitative PCR
13%
Sentinel Lymph Node
12%
Sentinel Lymph Node Biopsy
11%
T Cells
18%
Triple-negative Breast Cancer
11%
Tumor
26%
Tumor Immunity
15%
Vaccination
17%
Medicine and Dentistry
Antigen Specificity
9%
Axillary Lymph Node
15%
Breast Cancer
100%
Cancer
8%
Clinical Trial
6%
Cohort Analysis
5%
Cytokine
6%
Cytotoxic T-Cell
8%
Diseases
16%
Drug Megadose
6%
Epithelial Cell Adhesion Molecule
11%
Fine-Needle Aspiration
6%
Histopathology
5%
Interstitial Brachytherapy
8%
Intraductal Carcinoma
7%
Lymph Node
9%
Malignant Neoplasm
23%
Mammaglobin A
6%
Mammography
6%
Mastectomy
10%
Metastatic Breast Cancer
9%
Metastatic Carcinoma
17%
Micrometastasis
7%
Molecular Marker
5%
Neoadjuvant Chemotherapy
9%
Neoplasm
41%
Overall Survival
6%
Pancreas Adenocarcinoma
12%
Pancreas Cancer
7%
Papillary Thyroid Cancer
5%
Primary Tumor
6%
Prognostic Factor
5%
Prospective Cohort Study
5%
Quadrantectomy
13%
Quantitative Reverse Transcription Polymerase Chain Reaction
7%
Radiation Therapy
6%
Recurrent Disease
15%
Sentinel Lymph Node
12%
Sentinel Lymph Node Biopsy
12%
Surgery
7%
T Cell
10%
T-Cell Response
6%
Thyroidectomy
6%
Tumor Cell
8%
Tumor Progression
5%